ADAP

Adaptimmune Therapeutics
ADAP

Overview Fund Trends Analyst Outlook Journalist POV
Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

67 hedge funds and large institutions have $416M invested in Adaptimmune Therapeutics in 2017 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 21 increasing their positions, 14 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

more first-time investments, than exits

New positions opened: | Existing positions closed:

more capital invested

Capital invested by funds: $ → $

more repeat investments, than reductions

Existing positions increased: | Existing positions reduced:

more funds holding

Funds holding: →

0.63% more ownership

Funds ownership: 11.33% → 11.96% (+0.63%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
67
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
$88K
Puts
–
Net Calls
Net Calls Change

Top Buyers

1
+$27.4M
2
+$5.75M
3
+$3.37M
4
GAMA
Graticule Asia Macro Advisors
New York
+$3.24M
5
Millennium Management
Millennium Management
New York
+$2.8M

Top Sellers

1
-$5.34M
2
-$4.35M
3
-$3.88M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.45M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.41M
Name Holding Trade Value Shares
Change 		Change in
Stake
26
$827K
27
$819K
28
$819K
29
$754K
30
$683K
31
$669K
32
$598K
33
$471K
34
$446K
35
$406K
36
$369K
37
$365K
38
$328K
39
$320K
40
$308K
41
$254K
42
$234K
43
$230K
44
$206K
45
$205K
46
$199K
47
$197K
48
$182K
49
$180K
50
$170K
1
2
3